Table 1.
Baseline characteristics of included patients undergoing surgery for 20 primary solid tumors
| Characteristic | Die within one month | Survive beyond one month | Characteristic | Die within one month | Survive beyond one month |
|---|---|---|---|---|---|
| (N=15980) | (N=1116686) | (N=15980) | (N=1116686) | ||
| Tumor site | Age | 72.9 ± 14.0 | 60.1 ± 14.7 | ||
| Bladder | 1945 (12.2) | 69544 (6.2) | Race | ||
| Brain | 1634 (10.2) | 23396 (2.1) | NHW | 11832 (74.0) | 793221 (71.0) |
| Breast | 432 (2.7) | 301039 (27.0) | Minority | 4148 (26.0) | 323465 (29.0) |
| Cervix | 55 (0.3) | 11864 (1.1) | Marriage | ||
| Colorectum | 6211 (38.9) | 155255 (13.9) | Married | 7420 (46.4) | 695364 (62.3) |
| Esophagus | 75 (0.5) | 5079 (0.5) | Unmarried | 8560 (53.6) | 421322 (37.7) |
| Kidney | 664 (4.2) | 58690 (5.3) | Insurance | ||
| Larynx | 61 (0.4) | 5328 (0.5) | Insured | 13121 (82.1) | 975846 (87.4) |
| Liver | 238 (1.5) | 9457 (0.8) | Medicaid/Uninsured | 2859 (17.9) | 140840 (12.6) |
| Lung | 1353 (8.5) | 47107 (4.2) | Income | ||
| Melanoma | 191 (1.2) | 62729 (5.6) | Top 50% | 6422 (40.2) | 532110 (47.7) |
| Oral cavity | 119 (0.7) | 18300 (1.6) | Bottom 50% | 9558 (59.8) | 584576 (52.3) |
| Ovary | 707 (4.4) | 26664 (2.4) | Education | ||
| Pancreas | 395 (2.5) | 11175 (1.0) | Top 50% | 6640 (41.6) | 544476 (48.8) |
| Prostate | 245 (1.5) | 136270 (12.2) | Bottom 50% | 9340 (58.4) | 572210 (51.2) |
| Small intestine | 280 (1.8) | 7114 (0.6) | Residence | ||
| Stomach | 656 (4.1) | 15594 (1.4) | Metropolitan | 13812 (86.4) | 994561 (89.1) |
| Testis | 60 (0.4) | 15692 (1.4) | Rural | 2168 (13.6) | 122125 (10.9) |
| Thyroid | 159 (1.0) | 69535 (6.2) | Unemployment | ||
| Uterine | 500 (3.1) | 66854 (6.0) | Top 50% | 8922 (55.8) | 577853 (51.7) |
| Gender | Bottom 50% | 7058 (44.2) | 538833 (48.3) | ||
| Male | 8211 (51.4) | 453435 (40.6) | Poverty | ||
| Female | 7769 (48.6) | 663251 (59.4) | Top 50% | 9134 (57.2) | 568072 (50.9) |
| Age group | Bottom 50% | 6846 (42.8) | 548614 (49.1) | ||
| <50 | 861 (5.4) | 238015 (21.3) | SEER stage | ||
| 50-59 | 1725 (10.8) | 276960 (24.8) | Localized | 3845 (24.1) | 592017 (53.0) |
| 60-69 | 3105 (19.4) | 311907 (27.9) | Regional | 4952 (31.0) | 280494 (25.1) |
| >69 | 10289 (53.6) | 289804 (26.0) | Distant | 5286 (33.1) | 80874 (7.2) |
Note: Due to uncommon classification of SEER stage, cancer sites of brain, larynx and prostate were not considered for characteristic of SEER stage. All variables were expressed as frequency (percent), except for age as mean ± standard deviation;
Abbreviations: N, number; NHW, non-Hispanic white; SEER, Surveillance Epidemiology, and End Results.